KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $2.7 billion.

  • Alnylam Pharmaceuticals' Cash & Current Investments fell 1.71% to $2.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 billion, marking a year-over-year increase of 7.04%. This contributed to the annual value of $2.7 billion for FY2024, which is 10.53% up from last year.
  • According to the latest figures from FY2024, Alnylam Pharmaceuticals' Cash & Current Investments is $2.7 billion, which was up 10.53% from $2.4 billion recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Cash & Current Investments registered a high of $2.7 billion during FY2024, and its lowest value of $1.8 billion during FY2020.
  • For the 3-year period, Alnylam Pharmaceuticals' Cash & Current Investments averaged around $2.4 billion, with its median value being $2.4 billion (2023).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Cash & Current Investments rose by 29.39% in 2021 and then dropped by 8.71% in 2022.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Cash & Current Investments stood at $1.8 billion in 2020, then climbed by 29.39% to $2.4 billion in 2021, then declined by 8.71% to $2.2 billion in 2022, then climbed by 12.30% to $2.4 billion in 2023, then climbed by 10.53% to $2.7 billion in 2024.